Fennec (NASDAQ: FENC) CMO awarded 168 shares, holds 21,183

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported a compensation-related stock transaction. He acquired 168 Common Shares at $0.00 per share as a grant or award, representing shares released from restriction on an award originally granted on March 28, 2025. Following this vesting event, he directly holds 21,183 Common Shares. This is a routine equity compensation release rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sayad Pierre Sargis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	168	$0.00	--

Holdings After Transaction: Common Shares — 21,183 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 168 Common Shares Price per share: $0.00 per share Shares held after: 21,183 Common Shares +1 more

4 metrics

Shares acquired 168 Common Shares Grant/award acquisition on June 30, 2026

Price per share $0.00 per share Grant/award acquisition

Shares held after 21,183 Common Shares Direct ownership following the transaction

Transaction code A Grant, award, or other acquisition

Key Terms

Common Shares, Grant, award, or other acquisition, shares released from restriction, Form 4

4 terms

Common Shares financial

"He acquired 168 Common Shares at $0.00 per share as a grant or award"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction code “A,” meaning a grant, award, or other acquisition"

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025"

Form 4 regulatory

"The Form 4 uses transaction code “A,” meaning a grant, award, or other acquisition"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:38 PM Accepted by SEC EDGAR 07/01/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sayad Pierre Sargis

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	06/30/2026		A		168	A	$0	21,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Pierre Sayad	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did FENC’s Chief Medical Officer report?

Fennec Pharmaceuticals’ Chief Medical Officer reported acquiring 168 Common Shares as a stock award. The shares were released from restrictions on a prior grant dated March 28, 2025, and were not bought in the open market.

Was the FENC insider transaction an open-market buy or sale?

The transaction was not an open-market buy or sale. It was a grant or award acquisition of 168 Common Shares at $0.00 per share, reflecting restricted shares vesting from a prior equity award.

How many FENC shares does the Chief Medical Officer hold after this transaction?

After the transaction, the Chief Medical Officer directly holds 21,183 Common Shares. This figure reflects his updated ownership following the vesting and release of restrictions on the 168 awarded shares.

What is the significance of the footnote in this FENC Form 4 filing?

The footnote explains that the 168 shares represent shares released from restriction from shares awarded on March 28, 2025. This clarifies the transaction is a vesting event from a prior grant, not a new discretionary market trade.

What transaction code was used in the FENC Form 4 and what does it mean?

The Form 4 uses transaction code “A,” meaning a grant, award, or other acquisition. In this case, 168 Common Shares were acquired at no cost as part of the Chief Medical Officer’s equity compensation package.